Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260019 | 0.92 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL1258893 | 0.81 | MARS1 (0.52) | CNR1 | |
| SCHEMBL17645247 | 0.78 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL1986687 | 0.76 | GABRA2 (0.54) | CNR1 | |
| SCHEMBL4507104 | 0.74 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL762562 | 0.74 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL13722537 | 0.74 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL763008 | 0.74 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL30797899 | 0.74 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL5922301 | 0.73 | CNR1 (0.70) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | claimed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | claimed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | claimed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | claimed |
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | disclosed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | disclosed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | PYCR1, FARS2, WEE1 | CNR1 543/4885CNR2 846/4885 |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PYCR1, PRMT9, PRLHR | CNR1 125/4885CNR2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.